# Ipamorelin Research Literature — Mechanism and Study Findings

> Comprehensive summary of the ipamorelin research literature: GHS-R1a mechanism, bone and GI motility preclinical studies, one Phase 2 human trial, 2024-2025 cachexia data, and selectivity profile vs GHRP-2 and GHRP-6.

## Mechanism: GHS-R1a Selectivity

Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) — a G-protein-coupled receptor (GPCR) expressed on anterior pituitary somatotrophs, hypothalamic neurons, and enteric nervous system cells — with a Ki of approximately 1.0–1.5 nM. That affinity is three-to-five-fold lower than GHRP-2 (~0.3–0.4 nM Ki), but the selectivity profile diverges sharply.

Binding to pituitary somatotroph GHS-R1a activates Gq/11-protein signaling, triggering phospholipase C, IP3-mediated release of intracellular Ca2+, and a discrete pulse of GH secretion. The downstream GH pulse stimulates hepatic and peripheral IGF-1 production via GH receptor → JAK2/STAT5 signaling. IGF-1, in turn, engages the mTOR and PI3K/Akt pathways that mediate anabolic effects on protein synthesis and bone formation.

The defining pharmacological property of ipamorelin is its failure to engage the corticotroph (ACTH/cortisol) and lactotroph (prolactin) axes. In anesthetized rats and conscious swine, ipamorelin did not elevate ACTH or cortisol at doses exceeding 200-fold its GH-releasing ED50, and did not activate prolactin or TSH secretion. [1] A 2020 review designated ipamorelin the "prototypical selective GHS." [17]

## Bone and Body Composition Studies

Three primary rodent studies assessed ipamorelin's effects on bone formation and body composition.

Johansen et al. (1999) administered ipamorelin subcutaneously in three divided doses totaling 18, 90, or 450 mcg/day to adult female Sprague-Dawley rats for 15 days. Longitudinal bone growth rate increased in a dose-dependent manner from 42 mcm/day (control) to 44, 50, and 52 mcm/day in the three treatment groups. [2] Total circulating IGF-1 levels were unchanged, suggesting a local GH-dependent bone growth mechanism. [2]

Svensson et al. (2000) delivered ipamorelin continuously via osmotic minipump at 0.5 mg/kg/day for 12 weeks in young adult female Sprague-Dawley rats. Total tibial and vertebral bone mineral content (BMC) increased significantly. [4] Cortical bone enlargement was driven by periosteal expansion rather than increased volumetric bone mineral density. [4]

Andersen et al. (2001) studied ipamorelin in glucocorticoid-treated adult female Wistar rats (8 months) at 100 mcg/kg three times daily subcutaneously for three months. The periosteal bone formation rate increased four-fold compared with glucocorticoid alone. [3] Muscle maximum tetanic tension was also significantly improved. [3]

A 21-day chronic treatment protocol in young female Wistar rats demonstrated selective somatotroph sensitization: ipamorelin-pretreated animals showed elevated intracellular GH content following subsequent in vitro stimulation, with increased somatotroph secretory granule volume density. [5]

## GI Motility and Postoperative Ileus

Venkova et al. (2009) established preclinical activity: a single IV dose of 1 mg/kg reduced time to first bowel movement in a rat postoperative ileus model; repetitive dosing at 0.1 or 1 mg/kg four times daily significantly increased cumulative fecal pellet output, food intake, and body weight gain. [8]

Greenwood-Van Meerveld et al. (2012) characterized the mechanism: IV ipamorelin at 0.014 mcmol/kg reduced gastric radioactivity retention from 78% to approximately 52%, approaching non-operated control levels of 44%. [9] Ipamorelin normalized contractile response to acetylcholine via activation of cholinergic enteric neurons. [9]

Beck et al. (2014) conducted the Phase 2 human clinical trial (NCT00672074; N=114). Ipamorelin administered intravenously at 0.03 mg/kg twice daily for up to seven post-operative days was well tolerated (adverse events: 87.5% ipamorelin vs 94.8% placebo). Primary efficacy endpoint showed a 7.3-hour numeric improvement (25.3 h vs 32.6 h) that did not reach statistical significance (p=0.15). [10]

## Nitrogen Balance, Body Composition, and Cachexia

Aagaard et al. (2009) showed ipamorelin at 0.5 mg/kg/day reduced hepatic urea-nitrogen synthesis capacity by 20% (p<0.05), decreased urea cycle enzyme expression, and neutralized nitrogen balance in prednisolone-treated rats. [7]

Lall et al. (2001) documented GH-independent adiposity effects in both GH-deficient and GH-intact mice: elevated fat pad weights, serum leptin, and food intake via hypothalamic GHS-R1a activation, independently of changes in circulating GH. [6]

A 2024 Physiology & Behavior study found intraperitoneal ipamorelin inhibited cisplatin-induced weight loss by approximately 24% during the delayed phase (48–72 h post-cisplatin) in ferrets, via peripheral rather than central mechanism. [15]

## Structure-Activity Relationships and Analog Development

Ankersen et al. (1998) produced peptidomimetic analogs including NNC 26-0235, which achieved approximately 10% oral bioavailability in dogs at 1.8 mg/kg with a greater than 10-fold increase in basal GH, demonstrating the ipamorelin scaffold's utility for next-generation oral GHS design. [13] Intranasal bioavailability of ipamorelin itself is approximately 20% in rats, lower than related analogs (~50%). [11]

## References

[1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. DOI:10.1530/eje.0.1390552
[2] Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
[3] Andersen NB et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Hormone & IGF Research. 2001;11(5):266-272.
[4] Svensson J et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000;165(3):569-577.
[5] Jimenez-Reina L et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and Histopathology. 2002;17(3):707-714.
[6] Lall S et al. GH-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications. 2001;280(1):132-138.
[7] Aagaard NK et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Hormone & IGF Research. 2009;19(5):426-431.
[8] Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics. 2009;329(3):1110-1116.
[9] Greenwood-Van Meerveld B et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology. 2012;4:149-155.
[10] Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. DOI:10.1007/s00384-014-2030-8
[11] Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-1091.
[13] Ankersen M et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of Medicinal Chemistry. 1998;41(19):3699-3706.
[14] Mosinska P et al. Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists. Journal of Neurogastroenterology and Motility. 2017;23(4):458-468.
[15] GHS-R1a agonists anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. 2024;284:114644. DOI:10.1016/j.physbeh.2024.114644
[17] Ishida J et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.